Ayala Pharmaceuticals Reports First Patient Dosing of AL102 in P-III (RINGSIDE) trial for the Treatment of Desmoid Tumors
Shots:
- The first patient has been dosed in part B of the P-III (RINGSIDE) trial evaluating AL102 (1.2mg, qd) in 156 patients with desmoid tumors. The 1EPs of the trial are PFS & 2EPs incl. ORR, DoR, and patient-reported QoL measures
- The interim results from part A of the P-II (RINGSIDE) trial showed efficacy across all cohorts with early responses, confirmed PR was achieved @16wk. and 3 additional unconfirmed PRs over the follow-up period. The therapy was well tolerated with no dose-limiting toxicities & no grade 4/5 AEs.
- The long-term data from part A of the P-II (RINGSIDE) trial are expected in mid-2023. In Sept 2022, AL102 received FTD from the US FDA for the treatment of progressing desmoid tumors
Ref: Ayala | Image: Ayala
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
